EUCTR2016-004700-56-NL进行中（未招募）1 期
Exploratory study of neo-adjuvant treatment with carboplatin, paclitaxel and pembrolizumab in primary stage IV serous ovarian cancer
KI-AV0 个研究点目标入组 30 人开始时间: 2017年6月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Have given written informed consent for the trial.
- •2. Have a histologically proven diagnosis of primary high-grade serous ovarian, peritoneal, or fallopian tube cancer. Stage IV disease should ideally be cytologically or histologically proven.
- •3. Be equal or more then 18 years of age on day of signing informed consent.
- •4. Be willing and able to provide three tumor biopsies (1 FFPE, 2 fresh frozen) prior to start of treatment in which the tumor’s immunogenic mutational load can be determined by DNA and RNA sequencing.
- •5. Have a performance status of 0 or 1 on the ECOG Performance Scale.
- •6. Demonstrate adequate organ function as defined in the protocol
- •7. Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to first cycle of treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1. Has previously received treatment for ovarian, peritoneal, or fallopian tube cancer.
- •1a Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •1b Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent.
- •2. Has a known additional malignancy, unless treated with curative intent without chemotherapy at least five years ago. In situ cancers, basal cell carcinoma of the skin or squamous cell carcinoma of the skin that have undergone potentially curative therapy within the past five years may also be eligible.
- •3. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •5. Has a known history of active TB (Bacillus Tuberculosis)
- •6. Hypersensitivity to pembrolizumab or any of its excipients.
- •7. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •8. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •9. Has known history of, or any evidence of active, non-infectious pneumonitis.
- •10. Has an active infection requiring systemic therapy.
研究者
相似试验
已完成
不适用
Exploratory study of neo-adjuvant treatment with carboplatin, paclitaxel and pembrolizumab in primary stage IV serous ovarian cancerovarian cancerNL-OMON54749ederlands Kanker Instituut30
招募中
2 期
Phase II study of neo-adjuvant chemotherapy with combination therapy of gemcitabine and S-1 in patients with resectable pancreatic cancerresectable pancreatic cancerJPRN-UMIN000005912Tokai university, school of medicine50
已完成
不适用
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24
招募中
不适用
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancerBreast cancerJPRN-UMIN000029433Tokyo medical university70
招募中
不适用
Clinical efficacy study of neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for resectable pancreatic cancerpancreatic cancerJPRN-UMIN000046456Kyoto Katsura Hospital40